IgA Nephropathy Drug Pipeline

Aug 19, 2024

The first horse bearing Novartis’ IgAN treatment has reached the FDA’s approval milestone. FABHALTA is approved for use in treating IgAN patients who are at risk of swift disease progression, as evidenced by a urine protein-to-creatinine ratio of 1.5 g/g or higher. On August 8, the FDA approved the use of Novart...

Jul 22, 2024

Conventional  IgA nephropathy treatments include ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) to manage symptoms like high blood pressure. The only two FDA-approved treatments for managing IgAN are TARPEYO/KINPEYGO (budesonide) and FILSPARI (sparsentan)....

Sep 24, 2021

Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. Factors such as population aging, lifestyle-modifiable risk factors, a decline in early-life infectious diseases, sedentary lifestyle, unhealthy food habits have resulted in the emergence of chronic diseases as a major global hea...